Dr. Tai Camille Hunte, M.D. Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 9150 Estate Thomas, Suite 208, St Thomas, VI 00802 Phone: 340-774-1909 Fax: 340-777-9539 |
News Archive
Bariatric surgery is safe and, in many cases, beneficial for teenagers with morbid obesity who would otherwise face a heightened risk of developing severe health problems, including heart disease and stroke, according to a new study from Penn Medicine and the Children's Hospital of Philadelphia.
Aetna (NYSE: AET) is making it easier for members impacted by the wildfires burning in Southern California to refill prescriptions and access employee assistance and behavioral health programs. The company is monitoring the situation carefully, and will re-evaluate its medical and dental policies for members as necessary to help them access care in the fire-impacted county of Los Angeles, where many people face evacuations from their homes.
Despite one in 10 people worldwide having chronic kidney disease, a new global report - The Global Kidney Health Atlas - presented at this week's World Congress of Nephrology in Mexico City and compiled by the International Society of Nephrology and kidney health experts worldwide and published in JAMA- highlights the huge gaps in kidney disease care and prevention in both developed and developing countries, with many countries not prioritising kidney health.
Cardio3 BioSciences, soon to be renamed Celyad, a leader in engineered cell-therapy treatments today announced the infusion of the first patient enrolled in the Company's Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-cell therapy, in cancer patients suffering from acute myeloid leukemia (AML) or multiple myeloma (MM).
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented additional preclinical data at the American Association of Cancer Research (AACR) Advances in Brain Cancer Research Conference on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM).
› Verified 7 days ago